Danaher (NYSE:DHR) Issues Earnings Results, Hits Expectations

Danaher (NYSE:DHR) released its quarterly earnings results on Wednesday. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting the consensus estimate of $2.14, RTT News reports. Danaher had a net margin of 16.39% and a return on equity of 10.62%. During the same quarter in the prior year, the business posted $2.09 EPS.

Danaher Stock Down 5.9 %

Shares of Danaher stock opened at $233.34 on Wednesday. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. Danaher has a 12-month low of $225.42 and a 12-month high of $281.70. The firm has a market capitalization of $168.54 billion, a PE ratio of 44.65, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83. The stock’s fifty day moving average is $236.09 and its 200-day moving average is $253.66.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be paid a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.46%. The ex-dividend date is Friday, December 27th. Danaher’s dividend payout ratio is presently 20.61%.

Analyst Ratings Changes

Several research firms recently commented on DHR. Barclays cut their price target on Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 23rd. Royal Bank of Canada reduced their target price on Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Raymond James dropped their price target on shares of Danaher from $300.00 to $275.00 and set an “outperform” rating for the company in a research note on Tuesday, January 21st. Scotiabank began coverage on shares of Danaher in a research note on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price objective on the stock. Finally, StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. Six research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and a consensus price target of $285.81.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.